The SEC Declared Effective Bodisen
Biotech's Recent SB-2 Registration Statement and Bodisen
Successfully Hosts Global Fund Managers in Yang
Wednesday June 8, 9:30 am ET
NEW YORK--(BUSINESS WIRE)--June 8, 2005--Bodisen Biotech, Inc.,
(stock symbol: BBOI, website: /)
announced today that its filing of a Post Effective Amendment on
Form SB-2 was declared effective by the Securities and Exchange
Commission on May 27th, 2005.
Bodisen also announced that the company recently hosted U.S. and
European Institutions and Fund managers, for the fourth time in the
last twelve months at the company's headquarters in China. The two
day event allowed investors to visit Bodisen's new state of the art
manufacturing facility, witness the company's daily operations and
its strong growth potential. The investors were also introduced to a
number of key industry experts and local government officials, who
are involved with Bodisen's long term growth plans. For more
information and photos of Bodisen's facilities, please visit: /
Ms. Qiong Wang, CEO of Bodisen, commented, "We are pleased to
have the SEC review and then declared effective the SB-2
registration statement that we recently filed, which reflects our
ongoing commitments as a U.S. public company. Our first quarter 2005
financial report again reflected record earnings. We are on track to
achieving another record year in earnings with considerable growth.
I was also delighted by the strong interest shown in Bodisen from
global fund managers."
About Bodisen Biotech, Inc.
Utilizing proprietary technologies, Bodisen sells over 60
packaged products in 3 product categories throughout China: Organic
Compound Fertilizer; Organic Liquid Fertilizer; and Pesticides &
Insecticides. Bodisen's organic fertilizers can be absorbed by
plants within 48 hours while enriching soil conditions without the
damaging effects associated with chemical fertilizers.
Safe Harbor Statement
This press release may contain forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based
on the current expectations or beliefs of Bodisen Biotech, Inc.
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements.
Bodisen Biotech, Inc.
Source: Bodisen Biotech, Inc.